

ASX ANNOUNCEMENT

COMPANY SECRETARY APPOINTMENT AND RESIGNATION

SYDNEY, Friday, 30 October 2015: Cellmid Limited (ASX: CDY) wishes to advise that the Board of Directors has appointed Ms Aliceson Rourke as Company Secretary, effective 1 November 2015. Ms Rourke has been working at Cellmid as Chief Financial Officer since March 2015 and has been acting as Company Secretary for other ASX listed companies in the past.

The Board also wishes to advise the resignation of Mrs Lucy Rowe as Company Secretary, effective 1 November 2015. The Directors thank Mrs Rowe for her contribution to the Company during her tenure and wishes her well in her future endeavours.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company with lead drug candidates in oncology. The Company is developing innovative novel therapies and diagnostic tests for a number of cancer indications, in particular solid tumours. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel oncology target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au.

Investment in biotechnology companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.